Theravance Biopharma (TBPH) Stock Price, News & Analysis

Company Overview

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Key Stats

• Today's Range: $10.46 to $10.73
• 50-Day Range: $8.32 to $11.25
• 52-Week Range: $7.44 to $11.82
• Volume: 186,967 shs
• Average Volume: 276,056 shs
• Market Capitalization: $534.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.33
• Consensus Rating: Hold

Theravance Biopharma Stock Analysis - MarketRank™

Theravance Biopharma scored higher than 17% of companies evaluated by MarketBeat, and ranked 875th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Theravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Theravance Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Theravance Biopharma are expected to grow in the coming year, from ($1.09) to $0.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Theravance Biopharma is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Theravance Biopharma is -10.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Theravance Biopharma has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.26% of the float of Theravance Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Theravance Biopharma has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Theravance Biopharma has recently decreased by 5.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Theravance Biopharma does not currently pay a dividend.

Dividend Growth

Theravance Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.26% of the float of Theravance Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Theravance Biopharma has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Theravance Biopharma has recently decreased by 5.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 1.88

News Sentiment

Theravance Biopharma has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Theravance Biopharma this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for TBPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $300,000.00 in company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Theravance Biopharma is held by insiders.

Percentage Held by Institutions

99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TBPH Stock Analysis - Frequently Asked Questions

How have TBPH shares performed this year?

Theravance Biopharma's stock was trading at $9.41 at the beginning of the year. Since then, TBPH stock has increased by 13.6% and is now trading at $10.69.
View the best growth stocks for 2025 here.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.16. The biopharmaceutical company earned $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 24.79% and a negative net margin of 78.18%.
Read the conference call transcript.

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's top institutional shareholders include Vanguard Group Inc. (4.16%), Park West Asset Management LLC (3.61%), Nuveen LLC (0.75%) and Charles Schwab Investment Management Inc. (0.58%). Insiders that own company stock include Richard A Graham and Rhonda Farnum.
View institutional ownership trends.

How do I buy shares of Theravance Biopharma?

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/15/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TBPH
• Previous Symbol: NASDAQ:TBPHV
• CIK: 1583107
• Web: www.theravance.com
• Phone: (650) 808-6000
• Fax: N/A
• Employees: 359
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.33
• High Stock Price Target: $15.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +6.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.19 million
• Net Margins: -78.18%
• Pretax Margin: -64.39%
• Return on Equity: -24.79%
• Return on Assets: -13.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.97
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: $65.27 million
• Price / Sales: 8.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.28 per share
• Price / Book: 2.50

Miscellaneous

• Outstanding Shares: 50,001,000
• Free Float: 45,781,000
• Market Cap: $534.51 million
• Optionable: Optionable
• Beta: -0.09